Cite
De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays
MLA
Paul A. Lapchak, et al. “De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays.” Translational Stroke Research, vol. 2, Apr. 2011, pp. 209–17. EBSCOhost, https://doi.org/10.1007/s12975-011-0071-7.
APA
Paul A. Lapchak, David Schubert, & Pamela Maher. (2011). De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays. Translational Stroke Research, 2, 209–217. https://doi.org/10.1007/s12975-011-0071-7
Chicago
Paul A. Lapchak, David Schubert, and Pamela Maher. 2011. “De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays.” Translational Stroke Research 2 (April): 209–17. doi:10.1007/s12975-011-0071-7.